Qualcomm Stock: 5G Leader at a Bargain Price?
Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…
Sell
6
OLMA Quote, Financials, Valuation and Earnings
Last price:
$4.42
Seasonality move
:
-8.17%
Day range:
$4.39 - $4.60
52-week range:
$3.95 - $16.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.27x
Volume:
607.7K
Avg. volume:
814.8K
1-year change:
-61.88%
Market cap:
$252.7M
Revenue:
--
EPS (TTM):
-$2.18
Analysts' Opinion
-
Consensus RatingOlema Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $28.00, Olema Pharmaceuticals has an estimated upside of 534.92% from its current price of $4.41.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing -353.52% downside risk from its current price of $4.41.
Fair Value
-
According to the consensus of 5 analysts, Olema Pharmaceuticals has 534.92% upside to fair value with a price target of $28.00 per share.
OLMA vs. S&P 500
-
Over the past 5 trading days, Olema Pharmaceuticals has underperformed the S&P 500 by -0.03% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Olema Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Olema Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Olema Pharmaceuticals reported revenues of --.
Earnings Growth
-
Olema Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Olema Pharmaceuticals reported earnings per share of -$0.60.
Enterprise value:
37.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$101.5M | -$101.8M | -$135.9M | -$23.3M | -$37.6M | |
| EBITDA | -$101.2M | -$101.4M | -$135.5M | -$23.3M | -$37.5M | |
| Diluted EPS | -$2.51 | -$2.32 | -$2.18 | -$0.48 | -$0.60 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $129.1M | $308.3M | $225.1M | $282M | $218M | |
| Total Assets | $130.7M | $309.8M | $232M | $292.8M | $230.2M | |
| Current Liabilities | $5.3M | $8.9M | $12.6M | $16M | $30.7M | |
| Total Liabilities | $5.3M | $8.9M | $14.3M | $17.7M | $31.3M | |
| Total Equity | $125.4M | $300.9M | $217.7M | $275.1M | $198.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$81M | -$85M | -$96.5M | -$22.7M | -$27M | |
| Cash From Investing | $81.1M | $42.4M | -$10M | -$25.4M | $45.9M | |
| Cash From Financing | $1M | $133.2M | $25M | $130.6M | $92K | |
| Free Cash Flow | -$81.8M | -$85.1M | -$96.7M | -$22.7M | -$27M | |
OLMA
Sector
Market Cap
$252.7M
$38.4M
Price % of 52-Week High
26.53%
45.53%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.78%
1-Year Price Total Return
-61.88%
-39.05%
Beta (5-Year)
--
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$4.40
200-day SMA
Sell
Level
$9.96
Bollinger Bands (100)
Sell
Level
4.77 - 10.39
Chaikin Money Flow
Sell
Level
-19.4M
20-day SMA
Sell
Level
$4.62
Relative Strength Index (RSI14)
Sell
Level
39.73
ADX Line
Sell
Level
23.65
Williams %R
Neutral
Level
-52.0833
50-day SMA
Sell
Level
$5.29
MACD (12, 26)
Sell
Level
-0.34
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Sell
Level
-14.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Stock Forecast FAQ
In the current month, OLMA has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OLMA average analyst price target in the past 3 months is $28.00.
-
Where Will Olema Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Olema Pharmaceuticals share price will rise to $28.00 per share over the next 12 months.
-
What Do Analysts Say About Olema Pharmaceuticals?
Analysts are divided on their view about Olema Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Olema Pharmaceuticals is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Olema Pharmaceuticals's Price Target?
The price target for Olema Pharmaceuticals over the next 1-year time period is forecast to be $28.00 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OLMA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Olema Pharmaceuticals is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of OLMA?
You can purchase shares of Olema Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Olema Pharmaceuticals shares.
-
What Is The Olema Pharmaceuticals Share Price Today?
Olema Pharmaceuticals was last trading at $4.42 per share. This represents the most recent stock quote for Olema Pharmaceuticals. Yesterday, Olema Pharmaceuticals closed at $4.41 per share.
-
How To Buy Olema Pharmaceuticals Stock Online?
In order to purchase Olema Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is Buffett Buying and Selling Now?
In Q4 of last year, Warren Buffett made a few…
3 Safest Stocks to Buy Now
With the S&P 500 now in correction and stocks selling…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
59
GRRR alert for Mar 15
Gorilla Technology Group [GRRR] is up 29.72% over the past day.
Sell
49
SMTC alert for Mar 15
Semtech [SMTC] is up 21.28% over the past day.
Buy
62
PLPC alert for Mar 15
Preformed Line Products [PLPC] is up 17.38% over the past day.
